InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Vor Biopharma Inc.

VOR Clue Score3
United States Fiscal year ends December CIK 0001817229
$19.90 +4.03% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $19.90 +41.13% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 5 Feb 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2020Operating income−43.4Net income−43.3Fiscal year 2021Operating income−69.0Net income−68.9EPS, diluted−2.10Fiscal year 2022Operating income−93.4Net income−92.1EPS, diluted−2.33Fiscal year 2023Operating income−126.0Net income−117.9EPS, diluted−1.75Fiscal year 2024Operating income−121.2Net income−116.9EPS, diluted−34.03Fiscal year 2025Operating income−371.6Net income−696.0EPS, diluted−70.50
FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −43.4 −69.0 −93.4 −126.0 −121.2 −371.6
Net income −43.3 −68.9 −92.1 −117.9 −116.9 −696.0
Growth
EPS, diluted n/a −2.10 −2.33 −1.75 −34.03 −70.50

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−36.3Capital expenditure−4.2Free cash flow−40.5Dividends paid0.0Fiscal year 2021Operating cash flow−69.1Capital expenditure−3.9Free cash flow−73.0Dividends paid0.0Fiscal year 2022Operating cash flow−85.1Capital expenditure−8.5Free cash flow−93.6Dividends paid0.0Fiscal year 2023Operating cash flow−100.3Capital expenditure−1.1Free cash flow−101.4Dividends paid0.0Fiscal year 2024Operating cash flow−99.7Capital expenditure−0.2Free cash flow−99.9Dividends paid0.0Fiscal year 2025Operating cash flow−142.7Capital expenditure−0.9Free cash flow−143.7Dividends paid0.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −36.3 −69.1 −85.1 −100.3 −99.7 −142.7
Capital expenditure −4.2 −3.9 −8.5 −1.1 −0.2 −0.9
Free cash flow −40.5 −73.0 −93.6 −101.4 −99.9 −143.7
Growth
Dividends paid 0.0 0.0 0.0 0.0 0.0 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash48.5Shareholders’ equity−59.1Fiscal year 2021Cash119.8Shareholders’ equity216.3Fiscal year 2022Cash57.7Shareholders’ equity250.6Fiscal year 2023Cash31.4Shareholders’ equity150.7Fiscal year 2024Cash81.9Shareholders’ equity96.7Fiscal year 2025Cash396.5Shareholders’ equity−164.3
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 48.5 119.8 57.7 31.4 81.9 396.5
Shareholders’ equity −59.1 216.3 250.6 150.7 96.7 −164.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023† 31 Dec 2023 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
31.6 47.5 64.6 94.3 93.3 321.5
11.7 21.5 28.9 31.7 27.9 50.1
−43.4 −69.0 −93.4 −126.0 −121.2 −371.6
Growth
−43.3 −68.9 −92.1 −117.9 −116.9 −696.0
Growth
Per share
n/a −2.10 −2.33 −1.75 −34.03 −70.50
n/a −2.10 −2.33 −1.75 −34.03 −70.50
Growth
n/a 33.4 39.6 67.2 3.4 9.9
n/a 33.4 39.6 67.2 3.4 9.9
Growth +18.3% +69.9% −94.9% +187.3%

† The diluted share count jumps at 2023 and 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.